1. Home
  2. ASRT vs XGN Comparison

ASRT vs XGN Comparison

Compare ASRT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$13.95

Market Cap

76.0M

Sector

Health Care

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$2.85

Market Cap

74.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASRT
XGN
Founded
1995
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.0M
74.6M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
ASRT
XGN
Price
$13.95
$2.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$35.00
$9.14
AVG Volume (30 Days)
45.0K
328.2K
Earning Date
03-16-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,713,000.00
N/A
Revenue This Year
N/A
$12.51
Revenue Next Year
$16.87
$13.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$2.75
52 Week High
$13.90
$12.23

Technical Indicators

Market Signals
Indicator
ASRT
XGN
Relative Strength Index (RSI) 72.14 30.32
Support Level $0.69 N/A
Resistance Level N/A $3.89
Average True Range (ATR) 0.68 0.28
MACD 0.17 0.00
Stochastic Oscillator 98.27 9.64

Price Performance

Historical Comparison
ASRT
XGN

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: